← Back to Search

Polyphenol

Resveratrol for Coronary Artery Disease (SIRT-CVS Trial)

N/A
Waitlist Available
Led By Michael Robich, MD
Research Sponsored by MaineHealth
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 14 days
Awards & highlights

SIRT-CVS Trial Summary

This trial will test whether resveratrol can help reverse the negative effects of diabetes on the heart.

Who is the study for?
Adults over 18 with Type 2 diabetes and coronary artery disease scheduled for elective heart bypass surgery can join. They must not have severe kidney, liver, or blood clotting issues, be pregnant, or have certain infections like HIV. Heavy drinkers and those unlikely to follow the study plan are excluded.Check my eligibility
What is being tested?
The trial is testing if resveratrol (found in grapes/red wine) can improve heart health in diabetics by comparing it against a placebo. It looks at how it affects heart metabolism, inflammation, blood vessel function, and cardiac repair cells.See study design
What are the potential side effects?
While specific side effects aren't listed here, resveratrol could potentially cause digestive upset or allergic reactions in some people. The trial will monitor participants closely for any adverse effects.

SIRT-CVS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~14 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 14 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in endothelial function
Secondary outcome measures
Effects of resveratrol on caveolar function
Effects of resveratrol on molecular signaling

SIRT-CVS Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ResveratrolExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Trans-resveratrol
2012
Completed Phase 1
~80

Find a Location

Who is running the clinical trial?

MaineHealthLead Sponsor
71 Previous Clinical Trials
49,267 Total Patients Enrolled
American Heart AssociationOTHER
324 Previous Clinical Trials
4,933,738 Total Patients Enrolled
Michael Robich, MDPrincipal InvestigatorMaine Medical Center / MaineHealth

Media Library

Trans-resveratrol (Polyphenol) Clinical Trial Eligibility Overview. Trial Name: NCT03762096 — N/A
Type 2 Diabetes Research Study Groups: Resveratrol, Placebo
Type 2 Diabetes Clinical Trial 2023: Trans-resveratrol Highlights & Side Effects. Trial Name: NCT03762096 — N/A
Trans-resveratrol (Polyphenol) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03762096 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any opportunities for enrollment in this research endeavor currently available?

"As per the clinicaltrials.gov entry, this trial is not currently searching for participants; it was first posted on March 6th of 2018 and last edited on October 13th of 2022. Nevertheless, there are over 1300 other study opportunities actively recruiting individuals right now."

Answered by AI
~6 spots leftby Apr 2025